Publication | Closed Access

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

MedicineClinical TrialsImmune Checkpoint InhibitorCamrelizumab Versus PlaceboPharmacotherapyFirst-line TreatmentCancer TreatmentMetastatic Nasopharyngeal CarcinomaOncologyRadiation OncologyHealth Sciences